Drugs /

pc regimen

Back to Drugs List

Overview

NCI Definition [1]:
A regimen consisting of pentostatin and cyclophosphamide used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

Clinical Trials

View Clinical Trials for pc regimen

Pc regimen has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating pc regimen, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).

AR Expression, AR Positive, and ATM Loss are the most frequent biomarker inclusion criteria for pc regimen clinical trials.

Non-small cell lung carcinoma, adenocarcinoma of unknown primary, and breast carcinoma are the most common diseases being investigated in pc regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pc Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pc regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C63445

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.